Home › Companies › ZOMEDICA CORP. › 2023-2024
At ZOMEDICA CORP.'s 2 shareholder meetings in the 2023-2024 proxy season (held February 28, 2024 and June 6, 2024), 51 asset managers reported how they voted in their SEC Form N-PX filings, covering 216 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held June 6, 2024 — Approval, on an advisory basis, the executive compensation of the Corporation's named executive… — ZOMEDICA CORP.'s filing reports the proposal as not approved, with 47.3% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ZOMEDICA CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ZOMEDICA CORP.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 6, 2024: 10 items on ZOMEDICA CORP.’s Form 8-K, filed June 7, 2024: 8 elected · 1 approved · 1 not approved.
Meeting of February 28, 2024: 1 item on ZOMEDICA CORP.’s Form 8-K, filed February 29, 2024: 1 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore ZOMEDICA CORP. in the interactive database Compare manager voting policies
These tallies are ZOMEDICA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. ZOMEDICA CORP. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey Rowe | 110,760,471 | -- | -- | 61,531,927 | 183,131,920 | 64% | Elected | — |
| Elect Director: Robert Cohen | 104,897,697 | -- | -- | 67,394,701 | 183,131,920 | 61% | Elected | — |
| Elect Director: Chris Macleod | 110,762,680 | -- | -- | 61,529,718 | 183,131,920 | 64% | Elected | — |
| Elect Director: Pam Nichols | 113,970,507 | -- | -- | 58,321,891 | 183,131,920 | 66% | Elected | — |
| Elect Director: Johnny D. Powers | 117,642,702 | -- | -- | 54,649,696 | 183,131,920 | 68% | Elected | — |
| Elect Director: Sean Whelan | 110,747,785 | -- | -- | 61,544,613 | 183,131,920 | 64% | Elected | — |
| Elect Director: Rodney Williams | 110,993,136 | -- | -- | 61,299,262 | 183,131,920 | 64% | Elected | — |
| Elect Director: Larry Heaton | 103,625,393 | -- | -- | 68,667,005 | 183,131,920 | 60% | Elected | — |
| 2. Ratification of Independent Auditors | 288,330,513 | -- | -- | 67,093,805 | -- | 81% | Approved | — |
| 3. Advisory Vote on the Company's Executive Compensation The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statement for the Annual Meeting | 79,412,285 | 88,436,460 | 4,443,654 | -- | 183,131,919 | 47.3% | Not approved | — |
Source: ZOMEDICA CORP., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| ("Zomedica" or the "Company") was held on February 28, 2024 (the "Special Meeting"). At the Special Meeting, the shareholders voted on the following proposal | 136,067,529 | 206,789,223 | 2,109,080 | -- | -- | 40% | Not verified | — |
Source: ZOMEDICA CORP., Form 8-K, filed with the SEC on February 29, 2024 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a ZOMEDICA CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ZOMEDICA CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Chris MacLeod
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Chris Macleod”): 110,762,680 for, 61,529,718 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Jeffrey Rowe
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Jeffrey Rowe”): 110,760,471 for, 61,531,927 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Johnny D. Powers
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Johnny D. Powers”): 117,642,702 for, 54,649,696 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
60% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Larry Heaton
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Larry Heaton”): 103,625,393 for, 68,667,005 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 60% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Pamela Nichols
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Pam Nichols”): 113,970,507 for, 58,321,891 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
61% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Robert Cohen
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Robert Cohen”): 104,897,697 for, 67,394,701 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Rodney Williams, MBA
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Rodney Williams”): 110,993,136 for, 61,299,262 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect eight director nominees to serve as directors until the next annual meeting of shareholders: Sean Whelan
ZOMEDICA CORP.’s own tally for this item (“Elect Director: Sean Whelan”): 110,747,785 for, 61,544,613 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 : Election of Eight Directors Accordingly, stockholders elected all director nominees to hold office for terms expiring at the Company's 2025 annual meeting of stockholders.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Meeting held February 28, 2024.
100% of fund votes cast · no official result
Description as filed by funds: Special Resolution Authorizing Share Consolidation (also known as a Reverse Stock Split) To approve an amendment to the Corporation's Articles of Zomedica (''Articles'') to effect, at the discretion of the Board of Directors (the ''Board''), a share consolidation, also known as a reverse stock split, of the Corporation's common stock par value $0.01 per share, at a ratio of one (1) for eighty (80).
The 5 asset managers below reported 24,505,843 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 20,031,481 | 0 | 0 | 0 | For |
| ProShares | 2,573,819 | 0 | 0 | 0 | For |
| Fidelity | 1,894,368 | 0 | 0 | 0 | For |
| Nationwide | 4,873 | 0 | 0 | 0 | For |
| Victory Capital | 1,302 | 0 | 0 | 0 | For |
Meeting held February 28, 2024.
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
Description as filed by funds: To approve an amendment to the Corporation s Articles of Zomedica ( Articles ) to effect, at the discretion of the Board of Directors (the Board ), a share consolidation, also known as a reverse stock split, of the Corporation s common stock, par value $0.01 per share, at a ratio of one (1) for eighty (80).
The 2 asset managers below reported 432,334 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 20,000 | 0 | 0 | 0 | For |
Meeting held June 6, 2024.
Combines 8 wordings of this item as funds reported it.
47.3% Not approved · of votes cast
Description as filed by funds: Approval, on an advisory basis, the executive compensation of the Corporation's named executive officers
ZOMEDICA CORP.’s own tally for this item (“3. Advisory Vote on the Company's Executive Compensation The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statemen”): 79,412,285 for, 88,436,460 against — failed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “At the Annual Meeting, our shareholders voted on each of the following three matters: According to the final vote, the Company's stockholders approved proposals 1 and 2 and did not approve proposal 3.”
Support: 47.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Fund voting reports, all 6 managers: 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 7,280,555 | 0 | 0 | 0 | For |
| BlackRock | 6,729,581 | 0 | 0 | 0 | For |
| BROWN BROTHERS HARRIMAN & CO | 0 | 2,466,532 | 0 | 0 | Against |
| State Street | 2,140,381 | 0 | 0 | 0 | For |
| T. Rowe Price | 948,300 | 0 | 0 | 0 | For |
| Northern Trust | 848,085 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Vanguard | 346,549 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 99,888 | 0 | 0 | 0 | For |
| Atom Investors LP | 66,680 | 0 | 0 | 0 | For |
| Citadel | 63,144 | 0 | 0 | 0 | For |
| PINNACLE ASSOCIATES LTD | 0 | 15,000 | 0 | 0 | Against |
| Fisher Asset Management, LLC | 10,386 | 0 | 0 | 0 | For |
| CARY STREET PARTNERS INVESTMENT ADVISORY LLC | 10,300 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 10,200 | 0 | 0 | Against |
| Cresset Asset Management, LLC | 8,817 | 0 | 0 | 0 | For |
| EXENCIAL WEALTH ADVISORS, LLC | 8,733 | 0 | 0 | 0 | For |
| Pegasus Partners Ltd. | 8,730 | 0 | 0 | 0 | For |
| CAPTRUST FINANCIAL ADVISORS | 5,500 | 0 | 0 | 0 | For |
| Fidelis Capital Partners, LLC | 5,000 | 0 | 0 | 0 | For |
| Lionsbridge Wealth Management LLC | 5,000 | 0 | 0 | 0 | For |
| Cerity Partners LLC | 0 | 4,714 | 0 | 0 | Against |
| Fidelity | 4,183 | 0 | 0 | 0 | For |
| MERCER GLOBAL ADVISORS INC /ADV | 4,000 | 0 | 0 | 0 | For |
| Corient Private Wealth LLC | 3,500 | 0 | 0 | 0 | For |
Institutional-manager reports, all 47 managers: 19,026,011 for, 2,501,454 against, 15 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 6, 2024.
Combines 3 wordings of this item as funds reported it.
81% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2024;
ZOMEDICA CORP.’s own tally for this item (“2. Ratification of Independent Auditors”): 288,330,513 for, 67,093,805 withheld — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Accordingly, stockholders ratified the appointment of Grant Thornton, LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2023.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 6 asset managers below reported 24,241,131 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,185,075 | 0 | 0 | 0 | For |
| Fidelity | 6,539,847 | 0 | 0 | 0 | For |
| Charles Schwab | 412,334 | 0 | 0 | 0 | For |
| Gabelli | 100,000 | 0 | 0 | 0 | For |
| Nationwide | 2,597 | 0 | 0 | 0 | For |
| Victory Capital | 1,278 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 979,949,668 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 1.75% |
| 2 | Fidelity | 0.67% |
| 3 | Charles Schwab | 0.04% |
| 4 | Gabelli | 0.01% |
| 5 | Nationwide | <0.01% |
| 6 | Victory Capital | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 0.74% |
| 2 | BlackRock | 0.69% |
| 3 | BROWN BROTHERS HARRIMAN & CO | 0.25% |
| 4 | State Street | 0.22% |
| 5 | T. Rowe Price | 0.10% |
| 6 | Northern Trust | 0.09% |
| 7 | Charles Schwab | 0.04% |
| 8 | Vanguard | 0.04% |
| 9 | MELLON INVESTMENTS Corp | 0.01% |
| 10 | Atom Investors LP | <0.01% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Jeffrey Rowe | 1.39% | DEF14A |
| Robert Cohen | 1.08% | DEF14A |
| Geode Capital | 1.03% | 13F |
| Larry Heaton | 0.63% | DEF14A |
| Johnny D. Powers | 0.32% | DEF14A |
| State Street | 0.32% | 13F |
| Northern Trust | 0.18% | 13F |
| Tony K. Blair | 0.15% | DEF14A |
| Rodney Williams | 0.14% | DEF14A |
| Peter Donato | 0.13% | DEF14A |
Percentages above are of 979,949,668 shares outstanding, as reported by ZOMEDICA CORP. on its Form 10-Q dated May 9, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ZOMEDICA CORP.’s 10-Q dated May 9, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ZOMEDICA CORP. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “ZOMEDICA (ZOMDF) 2024 Annual & Special Meetings: Vote Results”, https://proxyvotesnow.com/company/zomedica-corp/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.